XOMA Corp. (Nasdaq: XOMA) will stop testing its arthritis treatment gevokizumab after it failed two mid-stage studies sending the stock price plummeting $2.62 to close at $6.82.
XOMA Halts Study
March 05, 2014 at 16:25 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.